SI
ACOR

Sofinnova Investments’s Acorda Therapeutics ACOR Stock Holding History

Sofinnova Investments’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,617
Closed -$1.49M – 86
2019
Q2 		$1.49M Buy
+1,617
New +$1.99M 0.14% 64

Other funds holding ACOR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sofinnova Investments's ACOR Position: Q3 2019 in Review

Sofinnova Investments sold out of Acorda Therapeutics (ACOR) in Q3 2019, closing a stake of 1,617 shares — an estimated $1.49M sold.

Sofinnova Investments first reported a position in ACOR in Q2 2019 and held it in 1 quarter. The position peaked at $1.49M in Q2 2019. 151 funds tracked by Wall St. Rank hold ACOR as of Q3 2019.

  • Sofinnova Investments reported no remaining Acorda Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Sofinnova Investments sold 1,617 Acorda Therapeutics shares in Q3 2019, an estimated $1.49M.
  • Sofinnova Investments first reported a position in Acorda Therapeutics in Q2 2019 and held it in 1 quarter.
  • Sofinnova Investments's Acorda Therapeutics position peaked at $1.49M in Q2 2019.
  • 151 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q3 2019.

Based on Sofinnova Investments's 13F filing for Q3 2019, filed 14 Nov 2019.